Epidermal growth factor receptor is often abundantly expressed in oesophageal cancer (Ozawa et al, 1987; Mukaida et al, 1991) and therefore we tested the ability of gefitinib to inhibit cell proliferation. Here, EGFR is linked to carcinoma of esophagus.